Literature DB >> 21558084

Relationship of blood pressure and obesity with inflammatory cytokines among African Americans.

Stephanie DeLoach1, Yonghong Huan, Scott W Keith, Maria P Martinez Cantarin, Bonita Falkner.   

Abstract

OBJECTIVES: Hypertension and obesity are major public health issues. Both conditions are highly prevalent among African Americans and contribute to the increased burden of cardiovascular disease in this group. Inflammation is considered to be an underlying process in both conditions. The authors sought to determine if there is an interaction between high blood pressure (HBP) and obesity that is associated with markedly elevated plasma levels of proinflammatory cytokines in African American adults.
METHODS: This study examined 484 African Americans, aged 18-45 years, including people with and without obesity, and also with and without HBP. People known to have diabetes were not enrolled. Plasma levels of high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), plasminogen activator inhibitor 1, tumor necrosis factor alpha (TNF-α), and adiponectin were measured. Participants also underwent an oral glucose tolerance test and measurement of blood pressure and body mass index (BMI).
RESULTS: There was no statistically significant interaction between obesity and HBP on plasma levels of adiponectin or the inflammatory cytokines. When both conditions were present, HBP and obesity had additive associations with the expected geometric mean ratios for IL-6 (1.44, 95% CI 1.18 to 1.75), TNF-α (1.31, 95% CI 1.11 to 1.53), hsCRP (2.55, 95% CI 1.99 to 3.26) and negative association with adiponectin (0.61, 95% CI 0.52 to 0.71). Compared with HBP, obesity had the predominant association with cytokine levels. An increase in cytokine plasma levels was detectable when BMI exceeded 25 kg/m2.
CONCLUSIONS: Biomarkers of inflammation in African Americans are strongly associated with BMI. A modest additive effect is found with HBP. Interventions to reduce obesity-related inflammation may impact cardiovascular disease outcomes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21558084     DOI: 10.1177/1753944711408757

Source DB:  PubMed          Journal:  Ther Adv Cardiovasc Dis        ISSN: 1753-9447


  6 in total

1.  Paradoxical Hyperadiponectinemia is Associated With the Metabolically Healthy Obese (MHO) Phenotype in African Americans.

Authors:  Ayo P Doumatey; Amy R Bentley; Jie Zhou; Hanxia Huang; Adebowale Adeyemo; Charles N Rotimi
Journal:  J Endocrinol Metab       Date:  2012-04-01

2.  Associations of cardiac structure with obesity, blood pressure, inflammation, and insulin resistance in African-American adolescents.

Authors:  Samuel S Gidding; Robert A Palermo; Stephanie S DeLoach; Scott W Keith; Bonita Falkner
Journal:  Pediatr Cardiol       Date:  2013-10-06       Impact factor: 1.655

3.  Obesity and life expectancy among long-lived Black adults.

Authors:  Pramil N Singh; Ralph W Clark; Patti Herring; Joan Sabaté; David Shavlik; Gary E Fraser
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-05-16       Impact factor: 6.053

4.  Serum adiponectin in relation to race-ethnicity and vascular risk factors in the Northern Manhattan Study.

Authors:  Hannah Gardener; Milita Crisby; Charlotte Sjoberg; Barry Hudson; Ronald Goldberg; Armando J Mendez; Clinton B Wright; Tatjana Rundek; Mitchell S V Elkind; Ralph L Sacco
Journal:  Metab Syndr Relat Disord       Date:  2012-11-05       Impact factor: 1.894

5.  Obesity associated inflammation in African American adolescents and adults.

Authors:  Stephanie DeLoach; Scott W Keith; Samuel S Gidding; Bonita Falkner
Journal:  Am J Med Sci       Date:  2014-05       Impact factor: 2.378

6.  Developmental trajectories of body mass index from childhood into late adolescence and subsequent late adolescence-young adulthood cardiometabolic risk markers.

Authors:  Kolade Oluwagbemigun; Anette E Buyken; Ute Alexy; Matthias Schmid; Christian Herder; Ute Nöthlings
Journal:  Cardiovasc Diabetol       Date:  2019-01-19       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.